Recent IPOs & Growth Stocks: Uncovering the Future Giants of the Stock Market

Tag: Funanc1al

Colorful illustration showing a cartoon delivery driver riding a rocket-powered scooter, surrounded by flying receipts, investor charts, burgers, and dollar bills raining down—symbolizing DoorDash’s explosive growth in both food and finance.

DoorDash Keeps Delivering — And Not Just Food

DoorDash isn’t just bringing food to your door—it’s bringing deals to Wall Street. From Deliveroo to SevenRooms, DASH is snapping up companies, stacking revenue, and gaining investor love. But can this delivery darling keep up the dash?

Read entire article

Tags: DASH, Dashers, Deliveroo, DoorDash, FoodTech, Funanc1al, Funanc1al Edge, Funanc1al for Investors, Funanc1al Investing, Funanc1alEdge, Funanc1alFun, Funanc1alHumor, Funanc1alStocks, GrowthStocks, InsiderScoops, InstitutionalOwnership, LocalCommerce, M&AWatch, SevenRooms, StockMarketHumor, TechAcquisitions, WoltAds
Cartoon of a CRISPR enzyme snipping DNA while hedge fund managers (ARKK & Baker Bros) cheer, and an insider waves a giant $1M buy ticket.

Intellia Therapeutics Update: Insider Buys, Institutional Muscle & Phase 3 Momentum

Intellia Therapeutics (NTLA) is up 20%, insiders are buying, ARKK and Baker Bros are holding or adding, and Phase 3 trials are moving faster than expected. Here’s why CRISPR medicine may be ready for prime time — or another plot twist.

Read entire article

Tags: ARKK, ARKK Fund, ATTR Amyloidosis, Baker Bros, Biotech, Biotech Investing, Biotech Investments, Biotech Partnerships, Biotech Stocks, Biotechnology, Biotechnology Innovation, Cathie Wood, Cathie Wood Stocks, CRISPR, CRISPR Gene Editing, Fun biotech, Funanc1al, Funanc1al Contrarian Plays, Funanc1al Insider Series, Funanc1al Stocks to Watch, FUNanc1alEdge, funanc1alstocks, gene editing, HAE, High Risk High Reward, Intellia, Intellia Therapeutics, investing humor, NTLA, Phase 3 biotech, Regeneron, Stocks & Fun